Patents Assigned to The Liposome Company, Inc.
  • Patent number: 6759057
    Abstract: Methods and compositions are described for the treatment of inflammatory diseases including the use of liposomes to deliver non-steroidal anti-inflammatory drugs. Drugs may be encapsulated in the liposomes during their preparation, or alternatively, are combined with the liposomes following their formation. The composition may include glycolipids such as galactolipids including digalactosyl diglyceride, and the liposomes may be made by a number of procedures. The compositions may be administered to mammals including humans.
    Type: Grant
    Filed: March 13, 1989
    Date of Patent: July 6, 2004
    Assignees: The Liposome Company, Inc., The University of British Columbia
    Inventors: Alan L. Weiner, Pieter R. Cullis
  • Patent number: 6573246
    Abstract: This invention provides lipids having: 1) a glycerol backbone; 2) a hydrocarbon chain, preferably saturated and containing 16 or 18 carbon atoms, attached to C-1 of the backbone by an ether linkage, 3) a methyl group attached to C-2 of the backbone, preferably by an ether linkage; and, 4) a sugar attached to C-3 of the glycerol backbone in either the alpha or beta anomeric configuration, the sugar being altered by modification of, or substitution for, one or more of its hydroxyl groups. Also provided herein are ether-lipid-containing compositions, as well as methods of administering such compositions to animals, for example, those afflicted with cancers, as well as various other diseases and disorders.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: June 3, 2003
    Assignees: The Liposome Company, Inc., The Research Foundation of the City University of New York
    Inventors: Robert Bittman, Ravi K. Erukulla, Andrew C. Peters, Eric G. Mayhew
  • Patent number: 6406713
    Abstract: Methods and compositions are described for nonliposomal lipid complexes in association with toxic hydrophobic drugs such as the polyene antibiotic amphotericin B. Lipid compositions are preferably a combination of the phospholipids dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) in about a 7:3 mole ratio. The lipid complexes contain a bioactive agent, and may be made by a number of procedures, at high drug:lipid ratios. These compositions of high drug:lipid complexes (HDLCs) may be administered to mammals such as humans for the treatment of infections, with substantially equivalent or greater efficacy and reduced drug toxicities as compared to the drugs in their free form. Also disclosed is a novel liposome-loading procedure, which may also be used in the formation of the HDLCs.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: June 18, 2002
    Assignee: The Liposome Company, Inc.
    Inventors: Andrew S. Janoff, Thomas D. Madden, Pieter R. Cullis, John J. Kearns, Anthony G. Durning
  • Patent number: 6392063
    Abstract: Provided herein is a taxane having a hydrocarbon attached at the 2′ and/or 7 positions, the hydrocarbon's alpha position being occupied by a “hydrolysis-promoting group” (“HPG”). In one embodiment, the hydrolysis promoting group is stereospecifically attached to the a-carbon of the hydrophobic taxane. The Substitution of an HPG for the methylene unit ordinarily occupying the alpha position allows for enhanced in vivo hydrolysis of the hydrocarbon-taxane bond, and hence, for enhanced taxane therapeutic activity. Also provided herein are taxane-containing compositions, and methods of administering taxanes to animals, including those afflicted with cancers or inflammatory diseases.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: May 21, 2002
    Assignee: The Liposome Company, Inc.
    Inventors: Shaukat Ali, J. Craig Franklin, Imran Ahmad, Eric Mayhew, Soumendu Bhattacharya, Gil Koehane, Andrew S. Janoff
  • Patent number: 6352716
    Abstract: Methods and compositions are described for the preparation of bioactive agents entrapped in lipid vesicles the bilayers of which comprise a salt form of an organic acid derivative of a sterol, such as the tris-salt form of a sterol hemisuccinate, and to bompositions comprising a mixtue of tris(hydroxymethyl)aminomethane salt of cholesteryl hemisuccinate with either an antifungal compound or a peptide. These compositions have various applications in vivo.
    Type: Grant
    Filed: August 18, 1993
    Date of Patent: March 5, 2002
    Assignee: The Liposome Company Inc.
    Inventors: Andrew S. Janoff, Mircea C. Popescu, Alan L. Weiner, Lois E. Bolcsak, Paul A. Tremblay, Christine E. Swenson
  • Patent number: 6294191
    Abstract: This invention provides liposomes containing one or more N-acylated phosphatidylethanolamines, such liposomes being useful for localizing the delivery of bioactive agents to cells.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: September 25, 2001
    Assignee: The Liposome Company, Inc.
    Inventors: Paul R. Meers, Tong Shangguan, Shaukat Ali, Andrew Janoff, Charles Pak
  • Patent number: 6291690
    Abstract: This invention provides a taxane derivative of the formula: wherein a hydrophobic organic moiety is attached to a taxane. R and R1 is each indepently H or a hydrophobic organic moiety, as long as at least one of R and R1 is not H. Attachment of a hydrophobic organic moiety to the taxane so as to obtain a taxane derivative generally stabilizes the association of the derivative with a lipid, including a liposomal lipid, carrier in the plasma of animals to which the derivative-carrier association is administered. Also provided herein is a composition containing the taxane derivative and a pharmaceutically acceptable medium; desirably, the medium also contains a lipid carrier, and the derivative is associated with the carrier. Further provided herein is a method of administering taxane derivatives to animals, for example, animals afflicted with cancers.
    Type: Grant
    Filed: May 9, 2000
    Date of Patent: September 18, 2001
    Assignee: The Liposome Company, Inc.
    Inventors: Eric Mayhew, J. Craig Franklin, Suresh Bhatia, Paul A. Harmon, Andrew S. Janoff
  • Patent number: 6261792
    Abstract: For use in a lipid-dependent diagnostic assay, a stable aqueous suspension of a phospholipid which normally has a hexagonal (HII) organization when dispersed in an aqueous medium without detergent, the suspension containing the phospholipid, a detergent, and an aqueous phase. In the stable suspension, the phospholipid remains in suspension at a temperature of 25° C. for at least one hour. The suspension is suitable for providing the phospholipid to an assay for lupus anticoagulants which includes the step of pre-incubating a test sample with the phospholipid.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: July 17, 2001
    Assignee: The Liposome Company, Inc.
    Inventors: Andrew S. Janoff, Joyce Rauch, Theodore F. Taraschi
  • Patent number: 6180137
    Abstract: Described herein are liposomes containing etherlipids of the formula: as well as a phosphatidylcholine, a sterol, and a headgroup-derivatized lipid. These liposomes are useful in a variety of therapeutic regimens, including the treatment of cancers and inflammatory disorders.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: January 30, 2001
    Assignee: The Liposome Company, Inc.
    Inventors: Eric Mayhew, Andrew S. Janoff, Imran Ahmad, Suresh K. Bhatia
  • Patent number: 6153736
    Abstract: This invention provides lipids having: 1) a glycerol backbone; 2) a hydrocarbon chain, preferably saturated and containing 16 or 18 carbon atoms, attached to C-1 of the backbone by an ether linkage; 3) a methyl group attached to C-2 of the backbone, preferably by an ether linkage; and, 4) a sugar attached to C-3 of the glycerol backbone in either the alpha or beta anomeric configuration, the sugar being altered by modification of, or substitution for, one or more of its hydroxyl groups. Also provided herein are ether-lipid-containing compositions, as well as methods of administering such compositions to animals, for example, those afflicted with cancers, as well as various other diseases and disorders.
    Type: Grant
    Filed: September 26, 1996
    Date of Patent: November 28, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Robert Bittman, Ravi K. Erukulla, Andrew C. Peters, Eric G. Mayhew
  • Patent number: 6143716
    Abstract: Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: November 7, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Paul R. Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J. Craig Franklin, Ravi K. Erukulla, Donna Cabral-Lilly
  • Patent number: 6120797
    Abstract: This invention provides liposomes containing one or more N-acylated phosphatidylethanolamines, such liposomes being useful for localizing the delivery of bioactive agents to cells.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: September 19, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Paul R. Meers, Tong Shangguan, Shaukat Ali, Andrew Janoff, Charles Pak
  • Patent number: 6118011
    Abstract: This invention provides a taxane derivative of the formula: ##STR1## wherein a hydrophobic organic moiety is attached to a taxane. R and R.sup.1 is each indepently H or a hydrophobic organic moiety, as long as at least one of R and R.sup.1 is not H. Attachment of a hydrophobic organic moiety to the taxane so as to obtain a taxane derivative generally stabilizes the association of the derivative with a lipid, including a liposomal lipid, carrier in the plasma of animals to which the derivative-carrier association is administered. Also provided herein is a composition containing the taxane derivative and a pharmaceutically acceptable medium; desirably, the medium also contains a lipid carrier, and the derivative is associated with the carrier. Further provided herein is a method of administering taxane derivatives to animals, for example, animals afflicted with cancers.
    Type: Grant
    Filed: November 27, 1996
    Date of Patent: September 12, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Eric Mayhew, J. Craig Franklin, Suresh Bhatia, Paul A. Harmon, Andrew S. Janoff
  • Patent number: 6107332
    Abstract: Provided herein is a taxane having a hydrocarbon attached at the 2' and/or 7 positions, the hydrocarbon's alpha position being occupied by a "hydrolysis-promoting group" ("HPG"). In one embodiment, the hydrolysis promoting group is stereospecifically attached to the .alpha.-carbon of the hydrophobic taxane. The Substitution of an HPG for the methylene unit ordinarily occupying the alpha position allows for enhanced in vivo hydrolysis of the hydrocarbon-taxane bond, and hence, for enhanced taxane therapeutic activity. Also provided herein are taxane-containing compositions, and methods of administering taxanes to animals, including those afflicted with cancers or inflammatory diseases.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: August 22, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Shaukat Ali, J. Craig Franklin, Imran Ahmad, Eric Mayhew, Soumendu Bhattacharya, Gil Koehane, Andrew S. Janoff
  • Patent number: 6090406
    Abstract: A high integrity liposome comprising at least one stabile lipid and at least one peptide-like therapeutic agent associated with said liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use. Immunizing dosage forms comprising a liposome and an immunogen, wherein said liposome and immunogen are present in an immunization dose. Additionally, a dosage form, including such form particularly adapted to producing an immune response, comprising a salt according to an organic acid derivative of a sterol and an immunogen wherein said organic acid derivative of a sterol and immunogen are present in an immunization dose, and method according to use is disclosed.
    Type: Grant
    Filed: February 26, 1990
    Date of Patent: July 18, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Mircea C. Popescu, Alan L. Weiner, Marie S. Recine, Andrew S. Janoff, Leonard Estis, Lynn D. Keyes, Carl R. Alving
  • Patent number: 6087325
    Abstract: Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: July 11, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Paul R. Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J. Craig Franklin, Ravi K. Erukulla, Donna Cabral-Lilly
  • Patent number: 6086851
    Abstract: This invention provides a composition containing a sized liposome comprising a lipid and an inducer; the sized liposome has a diameter of at most about 1 micron and the inducer is present in an amount effective to induce interdigitation-fusion of the sized liposome. Also provided herein are interdigitation-fusion liposomes and gels, and methods of making the same.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: July 11, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Lawrence T. Boni, Andrew S. Janoff, Sharma R. Minchey, Walter R. Perkins, Christine E. Swenson, Patrick L. Ahl, Thomas S. Davis
  • Patent number: 6083530
    Abstract: A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%, and liposomes may be loaded with drug immediately prior to use, eliminating stability problems related to drug retention in the liposomes. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: July 4, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Lawrence D. Mayer, Marcel B. Bally, Pieter R. Cullis, Richard S. Ginsberg, George N. Mitilenes
  • Patent number: 6030639
    Abstract: Provided herein is a method of administering a free arachidonic acid metabolite to an animal, the method involving administration of the free metabolite and an endocytosable particle. This method can be used to treat animals afflicted with disorders characterized by cell activation and adhesion, inflammation or toxemia. Also provided is a method of treating a animal for such disorders by administration to the animals of a composition containing an anti-disorder effective amount of an endocytosable particle.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: February 29, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Andrew S. Janoff, David F. Eierman
  • Patent number: RE39042
    Abstract: Described herein are liposomes containing etherlipids of the formula: as well as a phosphatidylcholine, a sterol, and a headgroup-derivatized lipid. These liposomes are useful in a variety of therapeutic regimens, including the treatment of cancers and inflammatory disorders.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: March 28, 2006
    Assignee: The Liposome Company, Inc.
    Inventors: Eric Mayhew, Andrew S. Janoff, Imran Ahmad, Suresh K. Bhatia